Risk assessment: Seasonal influenza 2013–2014 in the EU/EEA countries
This document is a routine and planned risk assessment of the 2013-2014 seasonal influenza in EU/EEA countries. Active circulation of influenza has started late in Europe in the 2013-2014 season, with a different timing across EU/EEA countries, states the annual ECDC risk assessment on seasonal influenza.
Risk assessment: Seasonal influenza 2014–2015 in the EU/EEA countries
This risk assessment covers the 2014–2015 influenza season in the European Union and European Economic Area (EU/EEA).
Risk assessment: Seasonal influenza 2012/13 in Europe (EU/EEA countries)
ECDC has produced an annual risk assessment of the seasonal influenza epidemics in Europe since the 2010/11 season following the model developed by ECDC during the 2009 pandemic. It gives an early description of the influenza season in the countries affected earliest, providing guidance and information to countries that are affected later, as influenza progresses across Europe over several months. It describes any specifics of the season, particularly in areas where public health or clinical actions are envisaged, as well as highlights areas of uncertainty where further work is required.
Risk assessment update: seasonal influenza, EU/EEA, 2016–2017
This updated risk assessment provides an overview of the current influenza situation in Europe.
Expert opinion on priority risk groups for influenza vaccination
This paper identifies and describes population groups at increased risk for severe outcomes of influenza (“risk groups”) and advocates vaccination for two major groups, namely a) persons in the older age group, usually 65 years and older; and b) persons with chronic medical conditions.
Rapid risk assessment on influenza A(H7N9) China, 12 April 2013
On 31 March 2013, Chinese authorities announced the identification of a novel reassortant A(H7N9) influenza virus isolated from three unlinked cases of severe respiratory disease in eastern China. This is the first time that human infection with avian influenza virus A(H7N9) has been identified.
Since then, human cases have continued to be reported from eastern China. As of 11 April, there were 38 laboratory-confirmed cases including ten deaths reported from four bordering provinces with a concentration of cases in and around Shanghai. Cases occur sporadically, without obvious epidemiological links. There is currently no confirmed human-to-human transmission.
Rapid Risk Assessment: Severe respiratory disease associated with Middle East respiratory syndrome coronavirus (MERS-CoV), 15th update, 9 March 2015
Since April 2012 and as of 7 March 2015, 1 082 cases (including 439 deaths) of Middle East respiratory syndrome coronavirus (MERS-CoV) have been reported by local health authorities worldwide.
Rapid Risk Assessment: Severe respiratory disease associated with Middle East respiratory syndrome coronavirus (MERS-CoV)
This updated ECDC rapid risk assessment contains options for action in relation to the outbreak of severe respiratory disease associated with Middle East respiratory syndrome coronavirus (MERS-CoV) in the Middle East.
Expert opinion on neuraminidase inhibitors for the prevention and treatment of influenza - review of recent systematic reviews and meta-analyses
This ECDC expert opinion confirms earlier assessments by ECDC and national authorities that there is no significant new evidence to support any changes to the approved indications and recommended use of neuraminidase inhibitors (NAIs) in EU/EEA Member States.
Updated Rapid Risk Assessment: Severe respiratory disease associated with Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
As of 17 June 2013, 64 cases of MERS-CoV had been reported worldwide, including 38 deaths. All cases remain associated (including indirect association following secondary person-to-person transmission in the UK, Italy, Tunisia and France) with transmission in the Middle East. The age of cases ranges from two years to 94 years (N=60 cases, information on age not available for four cases), with a median of 56 years. Overall 70% (43/61) of cases are males.
The reports of new infections in Saudi Arabia over the past few weeks indicate that there is an ongoing source of infection and low risk of transmission to humans in the Middle East.